A Phase 2 clinical trial involving corticorelin was updated to suspended status as of July 22, 2026. The trial, titled "CRF2 Agonist for the Treatment of Worsening Heart Failure," is registered as NCT06815471 on ClinicalTrials.gov.
Corticorelin is currently listed as an approved compound. The trial record identifies its status as SUSPENDED and its phase as Phase 2, without providing additional detail on the reason for the change in status.
No results, efficacy data, or safety findings were included in this update. The trial status reflects only the recruitment or conduct state as recorded, and does not indicate a conclusion about the compound's benefit or risk in heart failure treatment.
Readers interested in ongoing developments regarding this trial can refer to the official ClinicalTrials.gov listing for further updates as they become available. This brief reports only the status change as documented and does not interpret the cause or implications of the suspension.
For more background on corticorelin, including its approved uses and general profile, readers can consult the compound overview.